文献速递儿科与产科急症重症综合管理与镇静镇痛

降钙素原指导疑似早发型脓毒症新生儿抗生素疗程决策:多中心随机对照试验(NeoPIns)

Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns).
PubMed 文献 · Lancet · 2017-07-12
一句话结论在胎龄≥34周疑似早发型脓毒症新生儿中,降钙素原指导决策较标准治疗缩短抗生素疗程约10小时,但因再感染和死亡极少,非劣效性未能证明。

该多中心随机对照试验纳入荷兰(11家)、瑞士(4家)、加拿大(2家)和捷克(1家)医院胎龄≥34周、疑似早发型脓毒症需抗生素治疗的新生儿1710例,随机分为降钙素原指导组(866例)和标准治疗组(844例)。主要终点为出生后1个月内再感染或死亡的非劣效性(界值2.0%)以及抗生素疗程的优效性。降钙素原组抗生素疗程显著缩短(意向性分析:55.1 vs 65.0小时,p<0.0001;符合方案分析:51.8 vs 64.0小时,p<0.0001)。无一例脓毒症相关死亡,9例(<1%)可能出现再感染;非劣效性风险差为0.1%(95%CI -4.6至4.8),因再感染发生极少且无研究相关死亡,非劣效性未能证明。

要点

  • 胎龄≥34周疑似早发型脓毒症新生儿,降钙素原指导组抗生素疗程较标准组缩短(意向性分析55.1 vs 65.0小时,p<0.0001)。
  • 降钙素原组与标准组再感染或死亡风险差0.1%(95%CI -4.6至4.8),因事件极少,非劣效性未能证明。
  • 1710例中无一例脓毒症相关死亡,9例(<1%)可能出现再感染。
  • 排除标准包括生后第一周内手术或需住院的重大先天畸形。
  • 仅主要研究者对分组设盲,主治医师分层为四个风险类别后随机分组。

适用人群与场景

  • 胎龄34周或以上的新生儿,疑似早发型脓毒症需抗生素治疗。
  • 排除生后第一周内手术的新生儿和需住院治疗的重大先天畸形新生儿。
  • 场景为荷兰(11家)、瑞士(4家)、加拿大(2家)、捷克(1家)医院的新生儿病房。

处置流程与药物剂量

  • 主治医师将疑似早发型脓毒症新生儿按四个风险类别分层后,以1:1计算机生成列表按中心分层随机分配至降钙素原指导决策或标准治疗抗生素方案。
  • 降钙素原组抗生素疗程意向性分析55.1小时,标准组65.0小时;符合方案分析降钙素原组51.8小时,标准组64.0小时。

研究设计与关键结果

  • 多中心随机对照干预试验,纳入1710例胎龄≥34周疑似早发型脓毒症新生儿,降钙素原组866例,标准组844例;符合方案分析1408例(降钙素原组745例,标准组663例)。
  • 主要终点:降钙素原组抗生素疗程缩短(意向性分析55.1 vs 65.0小时,p<0.0001;符合方案分析51.8 vs 64.0小时,p<0.0001)。
  • 非劣效性终点:再感染或死亡风险差意向性分析0.1%(95%CI -4.6至4.8;降钙素原组5/866例[0.6%] vs 标准组4/844例[0.5%]),符合方案分析0.1%(95%CI -5.2至5.3;降钙素原组5/745例[0.7%] vs 标准组4/663例[0.6%])。
  • 无一例脓毒症相关死亡,9例(<1%)/1710例可能出现再感染。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(RCT)。
  • 非劣效性界值2.0%;仅主要研究者对分组设盲。
  • 局限:因再感染发生极少且无研究相关死亡,非劣效性未能证明。

对床旁实践的改变

  • 在胎龄≥34周疑似早发型脓毒症新生儿中,降钙素原指导决策可缩短抗生素疗程(意向性分析55.1 vs 65.0小时)。
  • 作者认为降钙素原指导决策在减少抗生素治疗方面优于标准治疗。
  • 因再感染和死亡极少,非劣效性未能证明,原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Up to 7% of term and late-preterm neonates in high-income countries receive antibiotics during the first 3 days of life because of suspected early-onset sepsis. The prevalence of culture-proven early-onset sepsis is 0·1% or less in high-income countries, suggesting substantial overtreatment. We assess whether procalcitonin-guided decision making for suspected early-onset sepsis can safely reduce the duration of antibiotic treatment.

METHODS: We did this randomised controlled intervention trial in Dutch (n=11), Swiss (n=4), Canadian (n=2), and Czech (n=1) hospitals. Neonates of gestational age 34 weeks or older, with suspected early-onset sepsis requiring antibiotic treatment were stratified into four risk categories by their treating physicians and randomly assigned [1:1] using a computer-generated list stratified per centre to procalcitonin-guided decision making or standard care-based antibiotic treatment. Neonates who underwent surgery within the first week of life or had major congenital malformations that would have required hospital admission were excluded. Only principal investigators were masked for group assignment. Co-primary outcomes were non-inferiority for re-infection or death in the first month of life (margin 2·0%) and superiority for duration of antibiotic therapy. Intention-to-treat and per-protocol analyses were done. This trial was registered with ClinicalTrials.gov, number NCT00854932.

FINDINGS: Between May 21, 2009, and Feb 14, 2015, we screened 2440 neonates with suspected early-onset sepsis. 622 infants were excluded due to lack of parental consent, 93 were ineligible for reasons unknown (68), congenital malformation (22), or surgery in the first week of life (3). 14 neonates were excluded as 100% data monitoring or retrieval was not feasible, and one neonate was excluded because their procalcitonin measurements could not be taken. 1710 neonates were enrolled and randomly assigned to either procalcitonin-guided therapy (n=866) or standard therapy (n=844). 1408 neonates underwent per-protocol analysis (745 in the procalcitonin group and 663 standard group). For the procalcitonin group, the duration of antibiotic therapy was reduced (intention to treat: 55·1 vs 65·0 h, p<0·0001; per protocol: 51·8 vs 64·0 h; p<0·0001). No sepsis-related deaths occurred, and 9 (<1%) of 1710 neonates had possible re-infection. The risk difference for non-inferiority was 0·1% (95% CI -4·6 to 4·8) in the intention-to-treat analysis (5 [0·6%] of 866 neonates in the procalcitonin group vs 4 [0·5%] of 844 neonates in the standard group) and 0·1% (-5·2 to 5·3) in the per-protocol analysis (5 [0·7%] of 745 neonates in the procalcitonin group vs 4 [0·6%] of 663 neonates in the standard group).

INTERPRETATION: Procalcitonin-guided decision making was superior to standard care in reducing antibiotic therapy in neonates with suspected early-onset sepsis. Non-inferiority for re-infection or death could not be shown due to the low occurrence of re-infections and absence of study-related death.

FUNDING: The Thrasher Foundation, the NutsOhra Foundation, the Sophia Foundation for Scientific research.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Stocker M, van Herk W, El Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017. PMID: 28711318. doi:10.1016/S0140-6736(17)31444-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。